Xueji Biotech Secures Tens of Millions in New Funding to Advance Platelet-Based Cell Therapies and Multifaceted Applications

On January 8, 2025, Suzhou HemaCell Biotechnology Co., Ltd. (hereinafter referred to as “HemaCell”) announced that it had secured tens of millions of yuan in equity investment from Zhongke Kangmei. The capital injection will be used to continue advancing the Investigational New Drug (IND) applications and formal clinical trials for multiple platelet-related pipelines of HemaCell, further propel the preclinical work on its lead platelet-based drug delivery pipeline, and expand businesses such as blood substitutes and medical aesthetics.

As the third company globally and the first in China to specialize in platelet regeneration through cell therapy, HemaCell leverages its core proprietary technology of directed differentiation of stem cells into platelets to effectively address the urgent issue of platelet shortages. By providing platelet components for transfusion systems that are traceable, clean, safe, and stably supplied, HemaCell is truly ushering in a second transfusion revolution for China and the world. With unique insight into market and industry opportunities, HemaCell targets critical pain points and enters diverse markets, covering areas such as blood transfusion, oncology, platelet disorders, sports medicine, medical aesthetics, and anti-aging. The company also maintains a strategic combination of short- and long-term product portfolios with a focused technological approach, emphasizing localization, cost reduction, and efficiency improvement.

According to Dr. Zhu Fangfang, founder of HemaCell, the company comprehensively advanced preclinical work on multiple transfusion-related pipelines in 2024. Some of these pipelines are undergoing dual regulatory filings in China and the United States, while simultaneously seeking orphan drug designations for various rare blood disorders. Key milestones are scheduled to be achieved in 2025. HemaCell is also fully advancing the development of new applications for platelet-based cell therapies in the field of anti-aging, having completed proof-of-concept studies in animal models and currently conducting preclinical research for multiple indications. Furthermore, HemaCell has established its own GMP-compliant facilities, leveraging internally cultivated process development, quality assurance, and production teams to scale up and manufacture its proprietary “First-in-Class” cell products, thereby establishing robust quality standards. Dr. Zhu noted that HemaCell currently maintains sound financial health, a stable team, and strong business momentum, ensuring steady corporate growth. In terms of financing strategy, HemaCell did not conduct any formal funding rounds in 2024; its collaboration and engagement with Zhongke Kangmei were primarily driven by considerations of industrial synergy and mutual development. She anticipates that investment from Zhongke Kangmei will bring additional value-added empowerment. Additionally, as HemaCell aims to initiate formal clinical trials for its first pipeline in 2025, it plans to commence its official Series B financing round in the second quarter.

Zhongke Kangmei stated: “The scarcity of HemaCell’s technology, the uniqueness of its market positioning, and the professionalism of its team are all impressive. The urgent unmet clinical demand for component blood products requires HemaCell’s regenerative solutions, while the substantial market potential offered by platelets presents opportunities for our future synergistic development with HemaCell. We look forward to HemaCell achieving key milestones in 2025 and realizing rapid corporate growth.”

Zhejiang Zhongke Kangmei Medical Technology Group is a healthcare industry group focused on the broader health sector, with an emphasis on strategic investment and operations. Its subsidiary brand, “Yuansong Medical Aesthetics,” adheres to the business philosophy of “simplicity, gratitude, sharing, perseverance, responsibility, dedication, and customer-first,” thereby establishing a brand image centered on “natural beauty and anti-aging.”